Drugs · Brain health technique

Anti-Tau Therapies (Monoclonal Antibodies)

Evidence grade: Experimental

Illustration for Anti-Tau Therapies (Monoclonal Antibodies)

Emerging biologics that target pathological tau aggregates to slow neurofibrillary tangle propagation. Agents under study include semorinemab (Genentech), gosuranemab (Biogen), tilavonemab (AbbVie), and BIIB076.

Practice
Drugs
Principle
Treatment
Tactic
Emerging Longevity / Neuroregenerative Agents
Evidence grade
Experimental
Strength of evidence
Low

How to practice Anti-Tau Therapies (Monoclonal Antibodies)

Access limited to research protocols for early Alzheimer’s or tauopathies. Requires tau PET or CSF confirmation and frequent infusions with imaging follow-up. Not approved for clinical use; future trials will clarify efficacy. Participation appropriate for biomarker-confirmed early disease in specialized research centers.

The evidence behind Anti-Tau Therapies (Monoclonal Antibodies)

Anti-tau antibodies are experimental lab-made immune proteins that bind tau outside cells. The antibodies aim to block tau's spread and slow tangle buildup. Early trials show good safety, and biomarker tests show the drugs engage tau. Evidence is early, though the biological case is strong.

Impact on brain health

Tau buildup tracks with memory and thinking decline more directly than amyloid does. That makes tau buildup a key treatment target. Trials so far show minimal improvement in memory and thinking.

Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science

Pair this with other habits from the same practice.

  • Evidence grade: Context Dependent

    Anti-Amyloid Monoclonal Antibodies

    FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

    Medium effort

  • Evidence grade: Context Dependent

    Antihypertensives

    Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

    Low effort · High cost

  • Evidence grade: Context Dependent

    GLP-1 Receptor Agonists

    A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.

See all 20 drugs techniques →

Take control of your brain health

BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.

How BetterBrain worksSee pricing